March 6, 2006 (Miami Beach) — A subcutaneous formulation of immunoglobulin replacement therapy ( Vivaglobin) produces results in primary immune deficiency diseases (PIDD) that are similar to those for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback